Bases estructurales de la degradación de CK1α inducida por la lenalidomida por la CRL4 (CRBN) ubiquitina ligasa
Video Experimental Relacionado
Updated: Mar 25, 2026
Georg Petzold1,2, Eric S Fischer1,2, Nicolas H Thomä1,2
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland.
Nature
|February 25, 2016
Resumen
La lenalidomida, un fármaco modulador inmunológico (IMiD, por sus siglas en inglés), reutiliza la CRL4 (CRBN) E3 ubiquitina ligasa para degradar proteínas como la CK1α. Este mecanismo explica la lenalidomida
Área de la Ciencia:
- Biología estructural
- Farmacología molecular
- Tratamiento del cáncer
Sus antecedentes:
- Los fármacos inmunomoduladores (IMiD) como la lenalidomida tratan las neoplasias hematológicas dirigidas a la CRL4 (CRBN) E3 ubiquitina ligasa.
- Los IMiD se unen a CRBN, alterando la especificidad del sustrato y llevando a la degradación de proteínas específicas.
Objetivo del estudio:
- Para aclarar la base estructural de la degradación de las proteínas inducida por la lenalidomida por CRL4 (CRBN).
- Comprender cómo la lenalidomida se dirige a CK1α e IKZF1 para su degradación.
Principales métodos:
- Cristalografía de rayos X para determinar la estructura de 2,45 Å del DDB1-CRBN unido a la lenalidomida y a la CK1α.
- Ensayos bioquímicos para evaluar la dependencia de la unión a las proteínas de los IMiD.
Principales resultados:
- La estructura cristalina revela CRBN y lenalidomida formando una interfaz de unión para CK1α.
- CK1α y IKZF1 vinculado a CRL4 ((CRBN) es estrictamente dependiente de la presencia de un IMiD.
- Tanto CK1α como IKZF1 utilizan un modo de unión similar al CRBN.
Conclusiones:
- El mecanismo de la lenalidomida implica la reutilización de CRL4 (CRBN) para degradar CK1α e IKZF1 a través de un modo de unión compartido.
- Esto proporciona una explicación mecánica de la eficacia de la lenalidomida en el tratamiento del síndrome mielodisplásico.
- Las interacciones proteína-proteína inducidas por pequeñas moléculas ofrecen una vía prometedora para el desarrollo de fármacos dirigidos a la degradación de proteínas.
Videos de Conceptos Relacionados
Regulated Protein Degradation
9.2K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.2K
Regulated Protein Degradation
3.3K
3.3K
Anaphase Promoting Complex
3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Covalently Linked Protein Regulators
9.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
9.9K
Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Export of Misfolded Proteins out of the ER
5.5K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.5K


